<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Infections of cerebrospinal fluid shunts</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Infections of cerebrospinal fluid shunts</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Infections of cerebrospinal fluid shunts</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Larry M Baddour, MD, FIDSA, FAHA</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Patricia M Flynn, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Thomas Fekete, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Morven S Edwards, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Allan R Tunkel, MD, PhD, MACP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Keri K Hall, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 29, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Cerebrospinal fluid (CSF) shunts are used in the setting of hydrocephalus to divert CSF to another part of the body for absorption. The approach to management of shunt infections is discussed here.</p><p>Indications for shunt placement and other issues related to hydrocephalus are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/111138.html" rel="external">"Hydrocephalus in children: Management and prognosis"</a> and  <a class="medical medical_review" href="/z/d/html/5069.html" rel="external">"Normal pressure hydrocephalus"</a>.)</p><p>General issues related to health care-associated meningitis and ventriculitis in adults, including post-neurosurgical infections and infections related to extraventricular drains, are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1302.html" rel="external">"Health care-associated meningitis and ventriculitis in adults: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/1301.html" rel="external">"Health care-associated meningitis and ventriculitis in adults: Treatment and prognosis"</a>.)</p><p>The management of bacterial meningitis in neonates, children, and adults is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/6016.html" rel="external">"Bacterial meningitis in the neonate: Treatment and outcome"</a> and  <a class="medical medical_review" href="/z/d/html/6010.html" rel="external">"Bacterial meningitis in children older than one month: Treatment and prognosis"</a> and  <a class="medical medical_review" href="/z/d/html/1290.html" rel="external">"Initial therapy and prognosis of community-acquired bacterial meningitis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/1283.html" rel="external">"Treatment of bacterial meningitis caused by specific pathogens in adults"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">SHUNT DEVICES</span><span class="headingEndMark"> — </span>The proximal portion of the shunt catheter is most commonly placed in one of the cerebral ventricles but may also be placed in an intracranial cyst or the lumbar subarachnoid space. The distal portion of the shunt can be internalized or externalized. Internalized shunts most commonly drain into the peritoneum (ventriculoperitoneal [VP] shunt), although, less commonly, they drain into the vascular space (ventriculoatrial [VA] shunt) or the pleural space (ventriculopleural shunt).</p><p>Externalized devices (ventriculostomy catheters, also called external ventricular drains [EVDs]) are temporary devices typically placed in the setting of acute hydrocephalus for intracranial pressure monitoring and therapeutic diversion of CSF. They may also be placed for interim management of hydrocephalus during antibiotic therapy for an infected internalized device that has been removed. (See  <a class="medical medical_review" href="/z/d/html/1302.html" rel="external">"Health care-associated meningitis and ventriculitis in adults: Clinical features and diagnosis", section on 'Ventricular catheter infection'</a>.)</p><p>Other externalized CSF drainage devices such as Ommaya reservoirs (for administration of antimicrobial drugs or cancer chemotherapy) can also become infected. The proximal portion of these devices is typically placed in the intraventricular space but may also be placed in an abscess cavity or tumor. The distal portion of the device is a reservoir placed under the scalp (less commonly in the lumbar space) and accessed via a needle when needed. (See  <a class="medical medical_review" href="/z/d/html/1302.html" rel="external">"Health care-associated meningitis and ventriculitis in adults: Clinical features and diagnosis", section on 'Infection of other CNS devices'</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">INCIDENCE AND RISK FACTORS</span><span class="headingEndMark"> — </span>The rate of internalized CSF shunt infection in most studies has ranged from approximately 5 to 15 percent [<a href="#rid1">1-11</a>]. Infections are most likely to be diagnosed during the initial month after placement [<a href="#rid3">3,11,12</a>].</p><p>Other risk factors for CSF shunt infection include [<a href="#rid4">4,12-14</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Patient factors:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Premature birth, especially when associated with intraventricular hemorrhage</p><p class="bulletIndent2"><span class="glyph">•</span>Younger age</p><p class="bulletIndent2"><span class="glyph">•</span>Previous shunt infection</p><p class="bulletIndent2"><span class="glyph">•</span>Certain causes of hydrocephalus (more likely after purulent meningitis, hemorrhage, or myelomeningocele)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Procedural factors:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Less experienced neurosurgeon</p><p class="bulletIndent2"><span class="glyph">•</span>Higher number of people traversing the operating theater during shunt placement</p><p class="bulletIndent2"><span class="glyph">•</span>Exposure to perforated surgical gloves</p><p class="bulletIndent2"><span class="glyph">•</span>Intraoperative use of a neuroendoscope</p><p class="bulletIndent2"><span class="glyph">•</span>Longer duration of the shunt procedure</p><p class="bulletIndent2"><span class="glyph">•</span>In those with ventriculoatrial (VA) shunting, insertion of the catheter below the level of the T7 vertebral body</p><p class="bulletIndent2"><span class="glyph">•</span>Improper patient skin preparation</p><p class="bulletIndent2"><span class="glyph">•</span>Shaving of skin</p><p class="bulletIndent2"><span class="glyph">•</span>Exposure of large areas of the patient's skin during the procedure</p><p class="bulletIndent2"><span class="glyph">•</span>Shunt revision, particularly if the patient has undergone ≥3 revisions</p><p class="bulletIndent2"><span class="glyph">•</span>Gastrostomy tube placement</p><p></p><p>Incidence and risk factors for infections related to external ventricular drains are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1302.html" rel="external">"Health care-associated meningitis and ventriculitis in adults: Clinical features and diagnosis", section on 'Ventricular catheter infection'</a>.)</p><p class="headingAnchor" id="H4"><span class="h1">MICROBIOLOGY AND PATHOGENESIS</span><span class="headingEndMark"> — </span>Shunt infections most frequently develop via colonization of the shunt with skin flora. This may occur at the time of shunt placement or postoperatively via breakdown of the wound or overlying skin. Early infection with skin flora is the most common type of CSF shunt infection; approximately one half of all shunt infections are due to coagulase-negative staphylococci and one third are due to <em>Staphylococcus aureus</em> [<a href="#rid2">2,15-20</a>]. Diphtheroids (such as <em>Cutibacterium </em>[formerly <em>Propionibacterium</em>]<em> acnes</em> and <em>Corynebacterium jeikeium</em>) can also cause shunt infection. (See  <a class="medical medical_review" href="/z/d/html/3158.html" rel="external">"Infection due to coagulase-negative staphylococci: Epidemiology, microbiology, and pathogenesis"</a>.)</p><p>Shunt infections may also develop via direct contamination of the distal end of the shunt or via hematogenous seeding. Distal-end contamination of ventriculoperitoneal shunts occurs in the setting of bowel perforation or peritonitis, whereas contamination of externalized devices occurs via catheter irrigation or tracking of microorganisms along the exit site. These infections tend to occur months after shunt placement and account for about 10 to 15 percent of shunt infections. They may be due to a variety of organisms including streptococci, gram-negative bacteria (including <em>Pseudomonas aeruginosa</em>), anaerobes, mycobacteria, and fungi [<a href="#rid21">21-34</a>].</p><p class="headingAnchor" id="H5"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>CSF shunt infections can present with few or no symptoms [<a href="#rid3">3,4</a>]. In some cases, symptoms develop only when infection has caused shunt obstruction and subsequent malfunction with clinical signs of increased intracranial pressure (eg, headache, nausea/vomiting, lethargy, or altered mental status). Meningeal symptoms may not be observed because communication between the infected ventricles and the meninges is usually absent (this is the reason for the shunt). Fever may or may not be present.</p><p>Another reason that the clinical manifestation may be subtle or absent is that commonly implicated pathogens, such as coagulase-negative staphylococci and <em>C. acnes</em>, are indolent, cause minimal inflammation, and are primarily pathogenic when prosthetic material is present [<a href="#rid4">4</a>]. In some cases, there may be only mechanical blockage as a result of biofilm formation in or on the catheter [<a href="#rid4">4,35,36</a>].</p><p>Symptoms may also present with localization to the distal internal (ventriculoperitoneal [VP], ventriculopleural, or ventriculoatrial [VA] shunts) or external end of the shunt:</p><p class="bulletIndent1"><span class="glyph">●</span>VP shunt infections may manifest with symptoms of peritonitis, including fever, abdominal pain, and anorexia. Large loculated pockets can develop in the peritoneum because of diminished CSF absorption in the setting of inflammation [<a href="#rid37">37</a>]. (See  <a class="medical medical_review" href="/z/d/html/1247.html" rel="external">"Spontaneous bacterial peritonitis in adults: Clinical manifestations"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients with ventriculopleural shunts, symptoms and signs of pleuritis in the absence of another etiology are suggestive of shunt infection [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>VA shunt infections may present with fever and evidence of bloodstream infection, which may develop via entry of infected CSF into the bloodstream or from an infected thrombus at the catheter tip. Subsequent endocarditis and its concomitant sequelae can occur, including septic pulmonary emboli and antibody-mediated sequelae such as glomerulonephritis and dermatologic manifestations [<a href="#rid38">38</a>]. (See  <a class="medical medical_review" href="/z/d/html/2143.html" rel="external">"Clinical manifestations and evaluation of adults with suspected left-sided native valve endocarditis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Distal external shunt infections typically present as evidence of soft tissue infection with swelling, erythema, tenderness, or purulent drainage.</p><p></p><p class="headingAnchor" id="H1995524319"><span class="h1">DIAGNOSTIC CRITERIA</span><span class="headingEndMark"> — </span>The diagnostic criteria for CSF shunt infections are the same as for health care-associated meningitis or ventriculitis, which are listed in the table  (<a class="graphic graphic_table graphicRef140116" href="/z/d/graphic/140116.html" rel="external">table 1</a>) and discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1302.html" rel="external">"Health care-associated meningitis and ventriculitis in adults: Clinical features and diagnosis", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H6"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>If clinical manifestations suggest the possibility of infection, a diagnostic evaluation should be initiated with CSF analysis, blood cultures, and imaging.</p><p class="headingAnchor" id="H7"><span class="h2">Cerebrospinal fluid</span><span class="headingEndMark"> — </span>Direct aspiration of the CSF shunt is preferred over ventricular tap or lumbar puncture when possible [<a href="#rid17">17,39</a>]. The CSF should be examined for white cell count with differential, glucose and protein concentrations, Gram stain, and culture. CSF cultures are the most important test for establishing the diagnosis of CSF shunt infections and should be obtained before starting antibiotics. In some cases, other studies can be useful, as discussed below. (See  <a class="medical medical_review" href="/z/d/html/1287.html" rel="external">"Clinical features and diagnosis of acute bacterial meningitis in adults", section on 'Cerebrospinal fluid analysis'</a> and  <a class="medical medical_review" href="/z/d/html/5968.html" rel="external">"Bacterial meningitis in children older than one month: Clinical features and diagnosis", section on 'Interpretation'</a>.)</p><p class="headingAnchor" id="H3194404363"><span class="h3">Cell count and differential</span><span class="headingEndMark"> — </span>Interpretation of CSF parameters can be challenging, and no single clinical or laboratory parameter, including fever, leukocytosis, CSF pleocytosis, or CSF protein and glucose, can reliably predict or exclude a shunt infection [<a href="#rid4">4,40</a>]. Central nervous system (CNS) device-related infections often manifest with less inflammation than bacterial meningitis; as a result, cell count abnormalities may be subtle and difficult to distinguish from postoperative inflammation. In a retrospective report of 11 pediatric shunt infections, for example, 5 had CSF white blood cell (WBC) counts less than 12/microL [<a href="#rid41">41</a>].</p><p>The WBC differential may be a useful clue to CSF shunt infections [<a href="#rid41">41,42</a>]. In one report of 129 shunt placements, a WBC count differential in CSF with &gt;10 percent neutrophils was 90 percent sensitive for predicting infection; the negative predictive value was 0.99. The presence of eosinophils in CSF is controversial with regard to infection specificity. While some studies indicate that the presence of eosinophils is rare in the setting of infection and should raise the possibility of inflammation due to shunt malfunction [<a href="#rid41">41,42</a>], another study found that CSF eosinophilia of &gt;8 percent of the differential count was associated with indolent infection [<a href="#rid43">43</a>]. A study that used &gt;1 percent eosinophils as the cutoff demonstrated an association with both infection and a variety of noninfectious entities [<a href="#rid44">44</a>] and has prompted continued controversy regarding the utility of CSF eosinophilia in the diagnosis of infection [<a href="#rid45">45</a>].</p><p class="headingAnchor" id="H2310511493"><span class="h3">Gram stain and culture</span><span class="headingEndMark"> — </span>CSF culture is the most important test for establishing a diagnosis of CSF shunt infection; it is critical for both pathogen identification and in vitro susceptibility testing to define an optimal treatment regimen. Ideally, CSF cultures should be obtained prior to starting antibiotic therapy. In one study of 326 children and adults, obtaining CSF prior to antibiotics increased the likelihood of a positive Gram stain (26 versus 13 percent) and CSF culture (66 versus 49 percent) [<a href="#rid46">46</a>]. A negative CSF Gram stain or culture does not exclude infection, particularly in patients who have received recent antibiotics [<a href="#rid4">4</a>].</p><p>If initial cultures are negative, they should be held for at least 10 days to increase the chance of recovering a slow-growing organism such as <em>C. acnes </em>[<a href="#rid4">4</a>]. If the initial CSF culture is negative and infection is considered likely, the CSF culture should be repeated. Positive cultures from the thioglycolate broth only should be interpreted with caution as they may represent a contaminant rather than infection, but, in patients who have received antibiotics, they could represent infection.</p><p>If a CSF shunt is removed in a patient suspected of having infection, the shunt components should be cultured [<a href="#rid4">4</a>]. However, if it is removed for a reason other than infection, cultures of the shunt components are <strong>not</strong> recommended. A positive CSF culture in a patient with pleocytosis and/or hypoglycorrhachia, or an increasing cell count, and clinical findings suspicious for ventriculitis or meningitis is indicative of CSF shunt infection.</p><p>If a patient with CSF shunt malfunction but no signs or symptoms suggestive of infection undergoes a CSF culture and that culture is positive, it could be a contaminant, but infection should also be considered [<a href="#rid4">4</a>]. In this situation, the CSF culture should be repeated. If the repeat culture grows the same organism, it is usually indicative of true infection.</p><p class="headingAnchor" id="H841291080"><span class="h3">Other tests</span><span class="headingEndMark"> — </span>Other tests can be helpful when Gram stain and culture results are negative or are inconclusive in establishing a diagnosis of CSF shunt infection:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>CSF lactate, CSF procalcitonin, and serum procalcitonin</strong> – An elevated CSF lactate or CSF procalcitonin (or the combination of both tests) may aid in the diagnosis of bacterial CSF shunt infection [<a href="#rid4">4,47-49</a>]. As an example, an elevated serum procalcitonin may be helpful for differentiating between CSF abnormalities due to surgery or intracranial hemorrhage and those due to bacterial infection since serum procalcitonin is often elevated in the setting of bacterial infection [<a href="#rid4">4</a>]. However, further study of the utility of these tests in patients with CSF shunt infections is necessary since some processes can cause both CSF lactate and serum procalcitonin elevations. In addition, in some studies, the use of these tests has been conflicting. Thus, elevated CSF lactate and serum procalcitonin should be considered adjuncts to clinical and other lab tests. When the prior probability of infection is low, a positive result might prompt reconsideration, but when it is high, a negative result should not dismiss the diagnosis. (See  <a class="medical medical_review" href="/z/d/html/1285.html" rel="external">"Cerebrospinal fluid: Physiology and utility of an examination in disease states", section on 'Lactate'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CSF molecular tests</strong> – Nucleic acid amplification tests can be helpful for detecting a specific pathogen and decreasing the time to making a diagnosis [<a href="#rid4">4</a>]. The methodology to conduct broad-range 16S (bacterial) rRNA polymerase chain reaction is becoming increasingly available in many centers. (See  <a class="medical medical_review" href="/z/d/html/1278.html" rel="external">"Molecular diagnosis of central nervous system infections"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>CSF beta-D-glucan and galactomannan</strong> – 1,3-beta-D-glucan, a cell wall component of many fungi including <em>Candida</em> and <em>Aspergillus</em> spp, is detected by the beta-D-glucan assay. Galactomannan is a polysaccharide that is a major constituent of <em>Aspergillus</em> cell walls and that is also present in the cell walls of certain other fungal species. Although most studies of the beta-D-glucan and galactomannan assays have involved testing serum specimens, some studies have suggested that they may be helpful for diagnosing fungal CNS infections. When fungal CSF shunt infection is suspected, it is reasonable to send CSF beta-D-glucan and galactomannan assays [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/z/d/html/15717.html" rel="external">"Diagnosis of invasive aspergillosis", section on 'Beta-D-glucan assay'</a> and  <a class="medical medical_review" href="/z/d/html/15717.html" rel="external">"Diagnosis of invasive aspergillosis", section on 'Galactomannan antigen detection'</a> and  <a class="medical medical_review" href="/z/d/html/2462.html" rel="external">"Clinical manifestations and diagnosis of candidemia and invasive candidiasis in adults", section on 'Beta-D-glucan assay'</a> and  <a class="medical medical_review" href="/z/d/html/1275.html" rel="external">"Approach to the patient with chronic meningitis", section on 'CSF examination and other laboratory testing'</a>.)</p><p></p><p class="headingAnchor" id="H9"><span class="h2">Blood cultures</span><span class="headingEndMark"> — </span>Blood cultures should be obtained along with CSF analysis when a CSF shunt infection is suspected and should be collected before antibiotics are started. Their yield is much higher in the setting of ventriculoatrial (VA) shunts than ventriculoperitoneal (VP) shunts (95 versus 20 percent in one series) [<a href="#rid17">17</a>]. Careful interpretation of positive blood cultures is necessary, particularly when only one set of cultures is positive and it grows skin flora.</p><p class="headingAnchor" id="H10"><span class="h2">Imaging</span><span class="headingEndMark"> — </span>Neuroimaging studies should be performed to look for evidence of ventriculitis or CSF obstruction (see  <a class="medical medical_review" href="/z/d/html/111138.html" rel="external">"Hydrocephalus in children: Management and prognosis", section on 'Shunt malfunction'</a>). Magnetic resonance imaging with gadolinium and diffusion-weighted imaging is the most useful modality for evaluating patients with possible CSF shunt infections [<a href="#rid4">4</a>].</p><p>Abdominal imaging (computed tomography or ultrasound) may be useful to identify CSF loculations at the distal end of VP shunts.</p><p class="headingAnchor" id="H11"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>There are no randomized trials addressing optimal treatment of CSF shunt infections. Management of CSF shunt infection should include removal of the device, external drainage, parenteral antibiotics, and shunt replacement once the CSF is sterile [<a href="#rid4">4,50-53</a>]. If device removal is not feasible, intraventricular antibiotics may be useful [<a href="#rid4">4</a>]. (See <a class="local">'Adjunctive intraventricular antibiotics in selected cases'</a> below.)</p><p>In 2017, the Infectious Diseases Society of America (IDSA) published guidelines for the management of healthcare-associated ventriculitis and meningitis [<a href="#rid4">4</a>]. Our recommendations are generally in keeping with the IDSA guidelines.</p><p class="headingAnchor" id="H12"><span class="h2">Device removal</span><span class="headingEndMark"> — </span>Optimal management of CSF shunt infection should include complete removal of the device, external drainage, and subsequent shunt replacement once CSF is sterile [<a href="#rid4">4,51,52,54,55</a>]. Removal of hardware is a critical part of management because, as noted above, some of the pathogens that cause CSF shunt infections form biofilms on prosthetic material, and antimicrobials are not able to eliminate organisms associated with biofilms and prosthetic material.</p><p>In one retrospective review of 50 CSF shunt infections, for example, 22 patients were treated with shunt removal, external drainage, and antibiotics; 17 patients were managed with shunt removal followed by immediate shunt replacement and antibiotics; and 11 patients received antibiotics without shunt removal [<a href="#rid52">52</a>]. The response rates were 95, 65, and 35 percent, respectively. In a cohort study that included 86 episodes of ventriculoperitoneal shunt infection, the only risk factor associated with treatment failure by multivariate analysis was shunt retention (odds ratio [OR] 46.04; 95% CI 5.30-399.88) [<a href="#rid55">55</a>]. Failure occurred more frequently among those who had one-stage shunt replacement compared with those who had two-stage shunt exchange (68 versus 11 percent; OR 17.88, 95% CI 4.33-73.85).</p><p>Management of intracranial pressure during the interval of device removal requires careful coordination between neurosurgeons and infectious disease consultants, particularly in shunt-dependent patients who require external drainage to control intracranial hypertension.</p><p>The management of the rare patient who cannot undergo hardware removal is discussed below. (See <a class="local">'Duration of antibiotics'</a> below.)</p><p class="headingAnchor" id="H13"><span class="h2">Antibiotic therapy</span></p><p class="headingAnchor" id="H2496822"><span class="h3">Systemic antibiotics</span></p><p class="headingAnchor" id="H2503154158"><span class="h4">Empiric therapy</span><span class="headingEndMark"> — </span>Parenteral antibiotic selection should be guided by the results of CSF Gram stain and culture. Pending these results, for adults, we recommend empiric therapy, taking into account local in vitro susceptibility results and bacteria previously isolated from the patient [<a href="#rid4">4</a>]. For most adults, we give <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a>  (<a class="graphic graphic_table graphicRef128911" href="/z/d/graphic/128911.html" rel="external">table 2</a>) and an agent to cover gram-negative bacilli, including <em>P. aeruginosa</em>. For adults, an agent to cover healthcare-associated gram-negative bacilli (<a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">ceftazidime</a> [2 g intravenously (IV) every 8 hours], <a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">cefepime</a> [2 g IV every 8 hours], or <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">meropenem</a> [2 g IV every 8 hours]) is appropriate. For adults with severe beta-lactam allergies (eg, anaphylaxis) and for whom meropenem is contraindicated, <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">aztreonam</a> (2 g IV every 6 to 8 hours) or <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">ciprofloxacin</a> (400 mg IV every 8 to 12 hours) should replace the cephalosporin or carbapenem.</p><p>For children, we recommend empiric therapy with <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> (15 mg/kg IV per dose every 6 hours; not to exceed 1 g per dose) and an agent to cover endogenous gram-negative pathogens (eg, <a class="drug drug_general" data-topicid="9221" href="/z/d/drug information/9221.html" rel="external">cefotaxime</a>, if available, [200 mg/kg IV per day in four divided doses; maximum daily dose 12 g] or <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a> [100 mg/kg IV per day in two divided doses; maximum daily dose 2 g]). Infection with <em>P. aeruginosa</em> or other resistant gram-negative bacilli is uncommon in children. We therefore do not include an antipseudomonal agent as part of the empiric regimen for most children, unless there are specific risk factors. If a multidrug-resistant gram-negative bacillus is a concern, <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">meropenem</a> (40 mg/kg IV per dose every 8 hours; maximum 2 grams/dose or 6 grams/day) is appropriate. The doses recommended above are intended for patients with normal renal function; dosing must be adjusted in patients with renal dysfunction.</p><p>For patients known to be colonized or infected at other anatomic sites with a highly antibiotic-resistant pathogen, the empiric regimen should be adjusted to treat this pathogen [<a href="#rid4">4</a>].</p><p class="headingAnchor" id="H1215623078"><span class="h4">Targeted therapy</span><span class="headingEndMark"> — </span>Subsequent antibiotic therapy should be tailored to culture and susceptibility results.</p><p class="headingAnchor" id="H152731461"><span class="h5">Staphylococci</span><span class="headingEndMark"> — </span>For gram-positive isolates, <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> monotherapy should be continued for methicillin-resistant pathogens, whereas methicillin-susceptible pathogens should be managed with <a class="drug drug_general" data-topicid="9674" href="/z/d/drug information/9674.html" rel="external">nafcillin</a> or <a class="drug drug_general" data-topicid="9724" href="/z/d/drug information/9724.html" rel="external">oxacillin</a>. Oral <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> is not routinely added to the above regimens but may augment treatment in the setting of refractory cases [<a href="#rid56">56</a>]. We also include rifampin as part of a combination regimen for those whose infected central nervous system (CNS) hardware cannot be removed.</p><p>In the event that cultures are negative but there is still a strong suspicion of CNS infection, we recommend empiric <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> for presumed staphylococcal infection. The dosing is summarized in the table  (<a class="graphic graphic_table graphicRef128911" href="/z/d/graphic/128911.html" rel="external">table 2</a>).</p><p><a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">Vancomycin</a> is the drug of choice for methicillin-resistant strains of <em>S. aureus</em> (MRSA) and coagulase-negative staphylococci that cause CSF shunt infections because it is the best studied and there is the most clinical experience with this agent. However, vancomycin has poor CSF penetration (1 percent in uninflamed meninges; 5 percent in inflamed meninges) [<a href="#rid54">54,57-59</a>]. In contrast, <a class="drug drug_general" data-topicid="9674" href="/z/d/drug information/9674.html" rel="external">nafcillin</a> and <a class="drug drug_general" data-topicid="9724" href="/z/d/drug information/9724.html" rel="external">oxacillin</a> have good CSF penetration in the setting of meningeal inflammation and are the drugs of choice for methicillin-susceptible strains of <em>S. aureus</em> (MSSA) that cause CSF shunt infections. Patients with MSSA infection who have an IgE-mediated allergy to penicillins can either be desensitized to nafcillin or oxacillin or receive vancomycin as an alternative agent [<a href="#rid4">4</a>]. <a class="drug drug_general" data-topicid="9214" href="/z/d/drug information/9214.html" rel="external">Cefazolin</a> should <strong>not</strong> be used for MSSA meningitis because it does not adequately penetrate into the CNS.</p><p><a class="drug drug_general" data-topicid="9674" href="/z/d/drug information/9674.html" rel="external">Nafcillin</a> and <a class="drug drug_general" data-topicid="9724" href="/z/d/drug information/9724.html" rel="external">oxacillin</a> are also the drugs of choice for the small proportion of coagulase-negative <em>Staphylococcus </em>strains that are confirmed to be methicillin-susceptible strains by specialized testing, such as using a gene probe for the <em>mecA</em> gene. If such specialized testing is not available, then <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> should be used because of the high frequency of methicillin-resistant strains and because of concerns about heteroresistance (subpopulations within a bacterial population that have varying degrees of phenotypic resistance) with coagulase-negative staphylococci that may not be detected on routine susceptibility testing. (See  <a class="medical medical_review" href="/z/d/html/467.html" rel="external">"Overview of antibacterial susceptibility testing", section on 'Basic concepts of antimicrobial resistance'</a>.)</p><p>For MRSA isolates with a <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> minimum inhibitory concentration (MIC) ≥1 mcg/mL, an alternative agent should be considered in patients who have not had the appropriate clinical or microbiologic response [<a href="#rid4">4</a>]. The IDSA guidelines recommend <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">linezolid</a>, <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a>, or <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> (TMP-SMX) as alternative agents when a beta-lactam or vancomycin cannot be used for staphylococcal meningitis and ventriculitis [<a href="#rid4">4</a>]. Among the alternative agents for staphylococcal meningitis (including MRSA), we generally favor linezolid in adults. The linezolid dose for adults is 600 mg IV or orally every 12 hours. However, the manufacturer states that empiric linezolid use in children with CNS infections is not recommended due to inconsistent concentrations in the CSF. Case reports have described successful treatment with linezolid of staphylococcal and vancomycin-resistant enterococcal CNS infections, including CSF shunt infections, despite the fact that linezolid is not bactericidal [<a href="#rid60">60,61</a>].</p><p>Because there is limited experience with alternative agents, CSF penetration is something of a proxy for potential utility in CNS device infections. <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">Linezolid</a> has good CSF penetration of approximately 66 percent [<a href="#rid54">54,62-64</a>], and TMP-SMX has moderately good CSF penetration (13 to 53 percent for TMP and 17 to 63 percent for SMX) [<a href="#rid54">54,65,66</a>]. In a rabbit meningitis model, CSF <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> penetration was 5 to 6 percent and achieved adequate concentrations [<a href="#rid54">54,67,68</a>]. Case reports and case series of patients with CNS infections caused by MRSA have evaluated linezolid [<a href="#rid61">61,69-72</a>], TMP-SMX [<a href="#rid54">54,65,73</a>], and daptomycin usually combined with <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> as alternative regimens [<a href="#rid74">74,75</a>]. Although there are insufficient data regarding the efficacy of these regimens for the treatment of meningitis caused by MRSA, these agents (particularly linezolid) are reasonable alternatives when <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> cannot be used (eg, in patients with allergies) or a patient has failed clinically or microbiologically. Further studies could be helpful in establishing the benefit of these agents for the treatment of meningitis, but they will be difficult to perform given the infrequency of need and the challenge of making comparisons to existing agents.</p><p class="headingAnchor" id="H2856902221"><span class="h5">Cutibacterium acnes</span><span class="headingEndMark"> — </span>For <em>C. acnes</em> infection, <a class="drug drug_general" data-topicid="9749" href="/z/d/drug information/9749.html" rel="external">penicillin G</a> is the agent of choice [<a href="#rid4">4</a>]. Alternative agents include third-generation cephalosporins (<a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a>, <a class="drug drug_general" data-topicid="9221" href="/z/d/drug information/9221.html" rel="external">cefotaxime</a>), <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a>, <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a>, and <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">linezolid</a>. (See  <a class="medical medical_review" href="/z/d/html/5538.html" rel="external">"Invasive Cutibacterium (formerly Propionibacterium) infections"</a>.)</p><p class="headingAnchor" id="H22216676"><span class="h5">Other causes</span><span class="headingEndMark"> — </span>Treatment of gram-negative bacillary meningitis and <em>Candida</em> infections of the CNS is described in detail separately. (See  <a class="medical medical_review" href="/z/d/html/1283.html" rel="external">"Treatment of bacterial meningitis caused by specific pathogens in adults", section on 'Gram-negative bacilli'</a> and  <a class="medical medical_review" href="/z/d/html/2453.html" rel="external">"Candida infections of the central nervous system", section on 'CNS shunts and other devices'</a>.)</p><p class="headingAnchor" id="H14"><span class="h3">Adjunctive intraventricular antibiotics in selected cases</span><span class="headingEndMark"> — </span>Adjunctive intraventricular antibiotics are not routinely necessary for treatment of CSF shunt infections. We generally reserve intraventricular antibiotics for infections that are refractory to appropriate systemic antibiotic therapy, infections caused by highly resistant organisms susceptible only to antimicrobials with poor CSF penetration, and infections in which the shunt cannot be removed. When we give intraventricular antibiotics, we use them as an adjunct to intravenous antibiotics (ie, in combination with intravenous therapy).</p><p>Administration, dosing, efficacy, and adverse effects of intraventricular antibiotics are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1301.html" rel="external">"Health care-associated meningitis and ventriculitis in adults: Treatment and prognosis", section on 'Intrathecal and intraventricular therapy'</a>.)</p><p class="headingAnchor" id="H15"><span class="h3">Duration of antibiotics</span><span class="headingEndMark"> — </span>No randomized prospective trials have been performed to determine the optimal duration of antibiotic therapy for CSF shunt infections [<a href="#rid4">4,50</a>].</p><p>We generally favor the following durations of antibiotics, in accordance with the IDSA [<a href="#rid4">4</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Infections caused by coagulase-negative staphylococci or <em>C. acnes</em> with no or minimal CSF pleocytosis, normal CSF glucose, and few symptoms or systemic features should be treated for 10 days.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Infections caused by coagulase-negative staphylococci or <em>C. acnes</em> with significant CSF pleocytosis, low CSF glucose, clinical symptoms, or systemic features should be treated for 10 to 14 days.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Infections caused by <em>S. aureus</em> or gram-negative bacilli with or without significant CSF pleocytosis, low CSF glucose, or clinical symptoms or systemic features should be treated for 10 to 14 days. Some experts treat infections caused by gram-negative bacilli for 21 days.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with repeatedly positive CSF cultures on appropriate antibiotics, treatment should be continued for 10 to 14 days following the last positive culture.</p><p></p><p>Decisions regarding antibiotic duration should be tailored to an individual patient's response to therapy; longer courses may be warranted in the setting of delayed or incomplete response.</p><p>In rare patients, complete device removal is not possible. In these cases, long-term oral suppressive antimicrobial therapy may be needed after completion of initial intravenous therapy.</p><p class="headingAnchor" id="H2672442100"><span class="h2">Timing of new shunt placement</span><span class="headingEndMark"> — </span>The optimal timing of new shunt placement has not been defined, but we generally favor the following approach, in accordance with the IDSA guidelines [<a href="#rid4">4</a>]; it should be noted that the timing of new shunt placement should be individualized based upon the isolated organism, the severity of the infection, and the improvement of CSF parameters and CSF sterilization in response to antibiotics [<a href="#rid4">4</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with coagulase-negative staphylococci or <em>C. acnes </em>infection <strong>without</strong> associated CSF abnormalities and with negative CSF cultures for 48 hours following externalization of the shunt, a new shunt can be placed as soon as the third day following removal of the infected shunt.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with coagulase-negative staphylococci or <em>C. acnes</em> infection <strong>with</strong> associated CSF abnormalities but with negative repeat CSF cultures, a new shunt can be placed after seven days of antibiotics. If repeat cultures are positive, antimicrobial treatment should be continued until CSF cultures remain negative for 7 to 10 consecutive days before a new shunt is placed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with infection caused by <em>S. aureus</em> or gram-negative bacilli, a new shunt can be placed 10 days after CSF cultures are negative.</p><p></p><p>A period without antibiotics is <strong>not</strong> recommended to verify clearance of infection before a new shunt is placed [<a href="#rid4">4</a>]. Close follow-up after placement of a new shunt is important to ensure that the infection has been adequately treated.</p><p class="headingAnchor" id="H280853501"><span class="h2">Monitoring the response to therapy</span><span class="headingEndMark"> — </span>Patients being treated for shunt infection should be monitored for a response to therapy using clinical parameters and CSF testing prior to replacing the shunt [<a href="#rid4">4</a>]. No data exist on the appropriate frequency of rechecking CSF cultures; we typically recheck them at 48- to 72-hour intervals. In patients without clear clinical improvement, additional CSF analysis should be performed. (See <a class="local">'Cerebrospinal fluid'</a> above.)</p><p>For patients who have an external ventricular drains (EVD) for an indication other than infection, daily CSF cultures and other CSF analysis are <strong>not</strong> recommended unless there is a clinical indication [<a href="#rid4">4</a>]. The rationale for this recommendation is that the results of such surveillance do not reliably predict infection and may increase the risk of iatrogenic infection. In one retrospective study, daily cultures did not identify infection before clinical signs and symptoms developed [<a href="#rid76">76</a>]. In a prospective study of patients with an external drainage device, CSF samples showed no significant differences in leukocyte count, protein concentration, glucose concentration, or CSF/blood glucose ratio between the patients in whom meningitis developed and a control group without EVD-associated meningitis during the first three days of infection or during the three days preceding the infection [<a href="#rid77">77</a>]. In addition, Gram staining had low sensitivity for detecting infection (18 percent on the first day of infection; 60 percent on the second day of infection). Thus, a positive Gram stain can be quite helpful, but a negative one is less useful.</p><p>In a prospective study of patients with EVDs in whom CSF was tested daily, the only parameter that correlated with a positive CSF culture was CSF cell count; peripheral white blood cell (WBC) count, CSF glucose, and CSF protein were not reliable predictors of infection [<a href="#rid78">78</a>]. Similarly, in a retrospective study of patients with EVDs that compared clinical and laboratory findings at the time of EVD insertion and at the time of documented infection, the two most reliable indicators of infection were increasing CSF pleocytosis (median WBC count 175/microL) and fever [<a href="#rid79">79</a>].</p><p class="headingAnchor" id="H16"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>Measures for prevention of CSF shunt infection include meticulous adherence to surgical and sterile technique (including topical antiseptic), short procedure times, and perioperative antibiotic prophylaxis [<a href="#rid80">80,81</a>]. Antibiotic-impregnated catheters may be beneficial. Prophylactic catheter exchange is not recommended.</p><p class="headingAnchor" id="H17"><span class="h2">Antibiotic prophylaxis</span><span class="headingEndMark"> — </span>Perioperative antibiotic prophylaxis is warranted in patients undergoing central nervous system (CNS) device placement [<a href="#rid4">4,82-85</a>]. Prolonged antibiotic prophylaxis for the duration of external ventricular drain (EVD) use is <strong>not</strong> recommended, as it has not been proven to be beneficial and might select for the emergence of resistant organisms [<a href="#rid4">4</a>].</p><p>For patients undergoing clean neurosurgical procedures, including CSF shunting procedures and intrathecal pump placement, we suggest <a class="drug drug_general" data-topicid="9214" href="/z/d/drug information/9214.html" rel="external">cefazolin</a> (2 g intravenously [IV] for adults &lt;120 kg adults and 3 g IV for adults ≥120 kg; 30 mg/kg IV for children) given 60 minutes prior to the incision. Cefazolin should be redosed at four-hour intervals until the surgery is over given the relatively short (about two-hour) half-life of cefazolin  (<a class="graphic graphic_table graphicRef87202" href="/z/d/graphic/87202.html" rel="external">table 3</a>). This approach is consistent with guidelines for antimicrobial prophylaxis for surgery that were published in 2013, representing the views of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America (IDSA), the Surgical Infection Society, and the Society for Healthcare Epidemiology of America [<a href="#rid81">81</a>]. </p><p>However, other experts use a different approach to antibiotic prophylaxis. As an example, although we prefer to administer antibiotics only prior to and during the surgical procedure, some guidelines suggest antibiotics be continued for as long as 24 hours postoperatively, as this is the duration that has been studied [<a href="#rid4">4</a>]. In addition, some experts prefer <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> instead of or in addition to <a class="drug drug_general" data-topicid="9214" href="/z/d/drug information/9214.html" rel="external">cefazolin</a>. The rationale for using vancomycin alone or with cefazolin is that coagulase-negative staphylococci, many of which are oxacillin-resistant, are commonly implicated in CSF shunt infections. Also, some add vancomycin to cefazolin in patients who had prior methicillin-resistant <em>S. aureus</em> (MRSA) colonization or infection or when the patient is at increased risk of MRSA colonization  (<a class="graphic graphic_table graphicRef53504" href="/z/d/graphic/53504.html" rel="external">table 4</a>). The dosing of vancomycin is 15 mg/kg (not to exceed 2 g) IV. It is important to note that vancomycin requires a prolonged infusion time and should be started two hours prior to the incision (compared with 60 minutes prior to the incision for most other agents) [<a href="#rid81">81</a>]. Only a single preoperative dose of vancomycin is necessary given its long half-life. (See  <a class="medical medical_review" href="/z/d/html/3157.html" rel="external">"Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Epidemiology", section on 'MRSA colonization'</a>.)</p><p>The benefit of antimicrobial prophylaxis for intracranial ventricular shunts was demonstrated in a meta-analysis of 15 observational studies that found systemic prophylactic antibiotics decrease rates of CSF shunt infection (odds ratio 0.52, 95% CI 0.36-0.74) [<a href="#rid82">82</a>]. A second meta-analysis of nine studies (seven randomized clinical trials and two retrospective cohort studies) showed similar findings, with the infection rate in the prophylactic antibiotic group being 5.9 compared with 10.7 percent in the control group (relative risk 0.55; 95% CI 0.38-0.81) [<a href="#rid86">86</a>].</p><p>Data regarding the possible benefit of antibacterial prophylaxis for EVDs are more limited, and only some studies have suggested a benefit [<a href="#rid87">87</a>]. Other studies have suggested no benefit, or even an association between antibiotic prophylaxis and the development of infections caused by resistant bacteria, but these studies had major limitations, such as being retrospective and underpowered to show a benefit [<a href="#rid4">4</a>].</p><p>To further reduce the risk of infection, some centers have advocated for the use of intrathecal antimicrobial administration in addition to intravenous antimicrobials as surgical site prophylaxis for new shunt placement [<a href="#rid88">88,89</a>]. However, given the absence of prospective, randomized trial data, we feel there is insufficient evidence to support the routine use of intrathecal antimicrobials as prophylaxis in patients with first-time shunt placement.</p><p>Antimicrobial prophylaxis for the prevention of surgical site infections is discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/4043.html" rel="external">"Antimicrobial prophylaxis for prevention of surgical site infection in adults"</a>.)</p><p class="headingAnchor" id="H18"><span class="h2">Antibiotic-impregnated catheters</span><span class="headingEndMark"> — </span>We favor the use of antibiotic-impregnated devices as they are likely to reduce the incidence of CSF shunt and EVD infections [<a href="#rid4">4</a>]. Although available data has generally been judged to be low-certainty, meta-analyses have found a reduction in infections with these catheters [<a href="#rid82">82,90-94</a>]. In addition, in a multicenter, single-blinded, randomized trial of 1605 patients comparing antibiotic-impregnated or silver-impregnated versus standard ventriculoperitoneal (VP) shunts, the percentage of individuals requiring a revision for infection was lower in the antimicrobial shunt group compared to the standard shunt and silver shunt groups (2, 6, and 6 percent, respectively) [<a href="#rid95">95</a>].</p><p class="headingAnchor" id="H19"><span class="h2">No role for prophylactic catheter exchange</span><span class="headingEndMark"> — </span>Prophylactic catheter exchange does not appear effective for preventing CSF shunt infection and is therefore not recommended [<a href="#rid4">4,82,96,97</a>]. As an example, in a trial of 103 patients with EVD randomly assigned to prophylactic catheter exchange or control groups, there was no difference in shunt infection rates (8 versus 4 percent, respectively) [<a href="#rid96">96</a>]. Similar lack of benefit was noted in a meta-analysis [<a href="#rid82">82</a>].</p><p class="headingAnchor" id="H3617162432"><span class="h2">Combined interventions</span><span class="headingEndMark"> — </span>Interventions that combine different prevention strategies appear to be effective in certain settings. The Hydrocephalus Clinical Research Network undertook an initiative in which centers agreed to develop an 11-step protocol to reduce CSF shunt infection rates; the protocol enforced sterile surgical techniques as well as the timing of antibiotic administration [<a href="#rid98">98</a>]. The infection rate decreased from 8.8 percent to 5.7 percent while using the protocol (relative risk, reduction of 36 percent, with a number needed to treat of 33), indicating that use of a standardized protocol is effective in reducing CSF shunt infection rates. However, antibiotic-impregnated shunt catheters were not examined in this investigation, and a subsequent study failed to demonstrate a reduction in infection rate with use of the 11-step protocol when these catheters were used [<a href="#rid99">99</a>].</p><p>In patients requiring placement of an EVD, following adoption of a simple protocol that bundled evidence-based infection prevention and control measures, ventriculitis rates declined from 6.3 percent in the baseline period to 0.8 percent during a three-year follow-up period [<a href="#rid100">100</a>]. In a subsequent study that examined the same cohort and included an additional four years of follow-up, the infection rate declined to 0 percent [<a href="#rid101">101</a>]. If these results can be replicated in other medical centers, they could provide support for a new guideline in the prevention of EVD infection.</p><p class="headingAnchor" id="H20"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology and microbiology</strong> – The rate of cerebrospinal fluid (CSF) shunt infection is about 5 to 15 percent. Risk factors include intraventricular hemorrhage, subarachnoid hemorrhage, and cranial fracture with CSF leak. (See <a class="local">'Incidence and risk factors'</a> above.)</p><p></p><p class="bulletIndent1">Skin flora account for the majority of infections associated with internalized or externalized CSF shunt devices. Shunt infections may also develop from the distal ends of internalized devices, leading to peritonitis or bloodstream infection with a variety of pathogens. (See <a class="local">'Microbiology and pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – Symptoms may be subtle or absent. Patients may present with manifestations of increased intracranial pressure or with symptoms localized to the distal end of the device. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – Diagnosis of CSF shunt infection can be challenging; CSF cell counts may be low and should be correlated with Gram stain and culture results. </p><p></p><p class="bulletIndent1">CSF cultures are the most important test for establishing the diagnosis of CSF shunt infections and external ventricular drain (EVD) infections and should be obtained before starting antibiotics. </p><p></p><p class="bulletIndent1">Blood cultures and imaging studies may be useful adjunctive tools. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial management</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Device removal</strong> – For patients with CSF shunt infections, we recommend device removal (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). Some patients may require external drainage to control intracranial hypertension. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Empiric antibiotic regimens</strong> – For adult patients, we suggest empiric parenteral antibiotic therapy with <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> <strong>plus </strong><a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">ceftazidime</a>, <a class="drug drug_general" data-topicid="9215" href="/z/d/drug information/9215.html" rel="external">cefepime</a>, or <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">meropenem</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent2">For children, we suggest empiric parenteral antibiotic therapy with vancomyc<strong>in plus</strong> <a class="drug drug_general" data-topicid="9221" href="/z/d/drug information/9221.html" rel="external">cefotaxime</a>, <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">ceftriaxone</a>, or <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">meropenem</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). </p><p></p><p class="bulletIndent2">These regimens provide coverage of coagulase-negative staphylococc<em>i, Staphylococcus aureus</em>, and gram-negative pathogens. (See <a class="local">'Empiric therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Subsequent management</strong> – Subsequent antibiotic therapy should be tailored to culture and susceptibility results. The role for intraventricular antibiotics is discussed in detail elsewhere. (See <a class="local">'Targeted therapy'</a> above and  <a class="medical medical_review" href="/z/d/html/1301.html" rel="external">"Health care-associated meningitis and ventriculitis in adults: Treatment and prognosis", section on 'Intrathecal and intraventricular therapy'</a>.)</p><p></p><p class="bulletIndent1">The duration of antibiotic therapy depends upon the implicated pathogen. (See <a class="local">'Duration of antibiotics'</a> above.)</p><p></p><p class="bulletIndent1">Patients should be monitored for a response to therapy using clinical parameters. In addition, CSF cultures should be checked serially to ensure that they have become negative. (See <a class="local">'Monitoring the response to therapy'</a> above.)</p><p></p><p class="bulletIndent1">The timing of new shunt placement should be individualized based upon the isolated organism, the severity of the infection, and the improvement of CSF parameters and CSF sterilization in response to antibiotics. (See <a class="local">'Timing of new shunt placement'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention of CSF shunt and device infection</strong> – For CNS device placement, we recommend antibiotic prophylaxis (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). We suggest <a class="drug drug_general" data-topicid="9214" href="/z/d/drug information/9214.html" rel="external">cefazolin</a> administered 60 minutes prior to incision and dosed every four hours during the procedure (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Alternative regimens, including the use of <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a>, are reasonable  (<a class="graphic graphic_table graphicRef87202" href="/z/d/graphic/87202.html" rel="external">table 3</a>). (See <a class="local">'Antibiotic prophylaxis'</a> above.)</p><p></p><p class="bulletIndent1">We suggest that antibiotic-impregnated CSF catheters be used (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Antibiotic-impregnated catheters'</a> above.)</p><p></p><p class="bulletIndent1">We suggest against prophylactic catheter exchange for prevention of infection (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Limited data suggest that prophylactic catheter exchange does not reduce infections. (See <a class="local">'No role for prophylactic catheter exchange'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Mayhall CG, Archer NH, Lamb VA, et al. Ventriculostomy-related infections. A prospective epidemiologic study. N Engl J Med 1984; 310:553.</a></li><li><a class="nounderline abstract_t">McGirt MJ, Zaas A, Fuchs HE, et al. Risk factors for pediatric ventriculoperitoneal shunt infection and predictors of infectious pathogens. Clin Infect Dis 2003; 36:858.</a></li><li><a class="nounderline abstract_t">Conen A, Walti LN, Merlo A, et al. Characteristics and treatment outcome of cerebrospinal fluid shunt-associated infections in adults: a retrospective analysis over an 11-year period. Clin Infect Dis 2008; 47:73.</a></li><li><a class="nounderline abstract_t">Tunkel AR, Hasbun R, Bhimraj A, et al. 2017 Infectious Diseases Society of America's Clinical Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis. Clin Infect Dis 2017.</a></li><li><a class="nounderline abstract_t">Renier D, Lacombe J, Pierre-Kahn A, et al. Factors causing acute shunt infection. Computer analysis of 1174 operations. J Neurosurg 1984; 61:1072.</a></li><li><a class="nounderline abstract_t">Younger JJ, Simmons JC, Barrett FF. Operative related infection rates for ventriculoperitoneal shunt procedures in a children's hospital. Infect Control 1987; 8:67.</a></li><li><a class="nounderline abstract_t">Quigley MR, Reigel DH, Kortyna R. Cerebrospinal fluid shunt infections. Report of 41 cases and a critical review of the literature. Pediatr Neurosci 1989; 15:111.</a></li><li><a class="nounderline abstract_t">Kontny U, Höfling B, Gutjahr P, et al. CSF shunt infections in children. Infection 1993; 21:89.</a></li><li><a class="nounderline abstract_t">Piatt JH Jr, Carlson CV. A search for determinants of cerebrospinal fluid shunt survival: retrospective analysis of a 14-year institutional experience. Pediatr Neurosurg 1993; 19:233.</a></li><li><a class="nounderline abstract_t">McGirt MJ, Leveque JC, Wellons JC 3rd, et al. Cerebrospinal fluid shunt survival and etiology of failures: a seven-year institutional experience. Pediatr Neurosurg 2002; 36:248.</a></li><li><a class="nounderline abstract_t">Vinchon M, Dhellemmes P. Cerebrospinal fluid shunt infection: risk factors and long-term follow-up. Childs Nerv Syst 2006; 22:692.</a></li><li><a class="nounderline abstract_t">van de Beek D, Drake JM, Tunkel AR. Nosocomial bacterial meningitis. N Engl J Med 2010; 362:146.</a></li><li><a class="nounderline abstract_t">Simon TD, Butler J, Whitlock KB, et al. Risk factors for first cerebrospinal fluid shunt infection: findings from a multi-center prospective cohort study. J Pediatr 2014; 164:1462.</a></li><li><a class="nounderline abstract_t">Al-Holou WN, Wilson TJ, Ali ZS, et al. Gastrostomy tube placement increases the risk of ventriculoperitoneal shunt infection: a multiinstitutional study. J Neurosurg 2018; :1.</a></li><li><a class="nounderline abstract_t">Davis SE, Levy ML, McComb JG, Masri-Lavine L. Does age or other factors influence the incidence of ventriculoperitoneal shunt infections? Pediatr Neurosurg 1999; 30:253.</a></li><li><a class="nounderline abstract_t">George R, Leibrock L, Epstein M. Long-term analysis of cerebrospinal fluid shunt infections. A 25-year experience. J Neurosurg 1979; 51:804.</a></li><li><a class="nounderline abstract_t">Schoenbaum SC, Gardner P, Shillito J. Infections of cerebrospinal fluid shunts: epidemiology, clinical manifestations, and therapy. J Infect Dis 1975; 131:543.</a></li><li><a class="nounderline abstract_t">Nelson JD. Cerebrospinal fluid shunt infections. Pediatr Infect Dis 1984; 3:S30.</a></li><li><a class="nounderline abstract_t">Younger JJ, Christensen GD, Bartley DL, et al. Coagulase-negative staphylococci isolated from cerebrospinal fluid shunts: importance of slime production, species identification, and shunt removal to clinical outcome. J Infect Dis 1987; 156:548.</a></li><li><a class="nounderline abstract_t">Diaz-Mitoma F, Harding GK, Hoban DJ, et al. Clinical significance of a test for slime production in ventriculoperitoneal shunt infections caused by coagulase-negative staphylococci. J Infect Dis 1987; 156:555.</a></li><li><a class="nounderline abstract_t">Lyke KE, Obasanjo OO, Williams MA, et al. Ventriculitis complicating use of intraventricular catheters in adult neurosurgical patients. Clin Infect Dis 2001; 33:2028.</a></li><li><a class="nounderline abstract_t">Filka J, Huttova M, Tuharsky J, et al. Nosocomial meningitis in children after ventriculoperitoneal shunt insertion. Acta Paediatr 1999; 88:576.</a></li><li><a class="nounderline abstract_t">Segal-Maurer S, Mariano N, Qavi A, et al. Successful treatment of ceftazidime-resistant Klebsiella pneumoniae ventriculitis with intravenous meropenem and intraventricular polymyxin B: case report and review. Clin Infect Dis 1999; 28:1134.</a></li><li><a class="nounderline abstract_t">Tush GM, Huneycutt S, Phillips A, Ward JD. Intraventricular quinupristin/dalfopristin for the treatment of vancomycin-resistant Enterococcus faecium shunt infection. Clin Infect Dis 1998; 26:1460.</a></li><li><a class="nounderline abstract_t">Vinchon M, Lemaitre MP, Vallée L, Dhellemmes P. Late shunt infection: incidence, pathogenesis, and therapeutic implications. Neuropediatrics 2002; 33:169.</a></li><li><a class="nounderline abstract_t">Baird C, O'Connor D, Pittman T. Late shunt infections. Pediatr Neurosurg 1999; 31:269.</a></li><li><a class="nounderline abstract_t">Greene KA, Clark RJ, Zabramski JM. Ventricular CSF shunt infections associated with Corynebacterium jeikeium: report of three cases and review. Clin Infect Dis 1993; 16:139.</a></li><li><a class="nounderline abstract_t">Knudsen JD, Nielsen CJ, Espersen F. Treatment of shunt-related cerebral ventriculitis due to Corynebacterium jeikeium with vancomycin administered intraventricularly. Case report. APMIS 1994; 102:317.</a></li><li><a class="nounderline abstract_t">Papadakis KA, Vartivarian SE, Vassilaki ME, Anaissie EJ. Stenotrophomonas maltophilia meningitis. Report of two cases and review of the literature. J Neurosurg 1997; 87:106.</a></li><li><a class="nounderline abstract_t">Bremer AA, Darouiche RO. Ventriculoperitoneal shunt infection due to Serratia marcescens. J Infect 2005; 50:138.</a></li><li><a class="nounderline abstract_t">Christenson JC, Pavia AT, Seskin K, et al. Meningitis due to Ochrobactrum anthropi: an emerging nosocomial pathogen. A report of 3 cases. Pediatr Neurosurg 1997; 27:218.</a></li><li><a class="nounderline abstract_t">Berner R, Heinen F, Pelz K, et al. Ventricular shunt infection and meningitis due to Bacillus cereus. Neuropediatrics 1997; 28:333.</a></li><li><a class="nounderline abstract_t">Midani S, Rathore MH. Mycobacterium fortuitum infection of ventriculoperitoneal shunt. South Med J 1999; 92:705.</a></li><li><a class="nounderline abstract_t">Chiou CC, Wong TT, Lin HH, et al. Fungal infection of ventriculoperitoneal shunts in children. Clin Infect Dis 1994; 19:1049.</a></li><li><a class="nounderline abstract_t">Braxton EE Jr, Ehrlich GD, Hall-Stoodley L, et al. Role of biofilms in neurosurgical device-related infections. Neurosurg Rev 2005; 28:249.</a></li><li><a class="nounderline abstract_t">Snowden JN, Beaver M, Smeltzer MS, Kielian T. Biofilm-infected intracerebroventricular shunts elicit inflammation within the central nervous system. Infect Immun 2012; 80:3206.</a></li><li><a class="nounderline abstract_t">Forward KR, Fewer HD, Stiver HG. Cerebrospinal fluid shunt infections. A review of 35 infections in 32 patients. J Neurosurg 1983; 59:389.</a></li><li><a class="nounderline abstract_t">Arze RS, Rashid H, Morley R, et al. Shunt nephritis: report of two cases and review of the literature. Clin Nephrol 1983; 19:48.</a></li><li><a class="nounderline abstract_t">Noetzel MJ, Baker RP. Shunt fluid examination: risks and benefits in the evaluation of shunt malfunction and infection. J Neurosurg 1984; 61:328.</a></li><li><a class="nounderline abstract_t">Meredith FT, Phillips HK, Reller LB. Clinical utility of broth cultures of cerebrospinal fluid from patients at risk for shunt infections. J Clin Microbiol 1997; 35:3109.</a></li><li><a class="nounderline abstract_t">McClinton D, Carraccio C, Englander R. Predictors of ventriculoperitoneal shunt pathology. Pediatr Infect Dis J 2001; 20:593.</a></li><li><a class="nounderline abstract_t">Lan CC, Wong TT, Chen SJ, et al. Early diagnosis of ventriculoperitoneal shunt infections and malfunctions in children with hydrocephalus. J Microbiol Immunol Infect 2003; 36:47.</a></li><li><a class="nounderline abstract_t">Tung H, Raffel C, McComb JG. Ventricular cerebrospinal fluid eosinophilia in children with ventriculoperitoneal shunts. J Neurosurg 1991; 75:541.</a></li><li><a class="nounderline abstract_t">Fulkerson DH, Boaz JC. Cerebrospinal fluid eosinophilia in children with ventricular shunts. J Neurosurg Pediatr 2008; 1:288.</a></li><li><a class="nounderline abstract_t">Heidemann SM, Fiore M, Sood S, Ham S. Eosinophil activation in the cerebrospinal fluid of children with shunt obstruction. Pediatr Neurosurg 2010; 46:255.</a></li><li><a class="nounderline abstract_t">Rogers T, Sok K, Erickson T, et al. Impact of Antibiotic Therapy in the Microbiological Yield of Healthcare-Associated Ventriculitis and Meningitis. Open Forum Infect Dis 2019; 6:ofz050.</a></li><li><a class="nounderline abstract_t">Li Y, Zhang G, Ma R, et al. The diagnostic value of cerebrospinal fluids procalcitonin and lactate for the differential diagnosis of post-neurosurgical bacterial meningitis and aseptic meningitis. Clin Biochem 2015; 48:50.</a></li><li><a class="nounderline abstract_t">Hill E, Bleck TP, Singh K, et al. CSF lactate alone is not a reliable indicator of bacterial ventriculitis in patients with ventriculostomies. Clin Neurol Neurosurg 2017; 157:95.</a></li><li><a class="nounderline abstract_t">Grille P, Verga F, Biestro A. Diagnosis of ventriculostomy-related infection: Is cerebrospinal fluid lactate measurement a useful tool? J Clin Neurosci 2017; 45:243.</a></li><li><a class="nounderline abstract_t">Whitehead WE, Kestle JR. The treatment of cerebrospinal fluid shunt infections. Results from a practice survey of the American Society of Pediatric Neurosurgeons. Pediatr Neurosurg 2001; 35:205.</a></li><li><a class="nounderline abstract_t">James HE, Walsh JW, Wilson HD, et al. Prospective randomized study of therapy in cerebrospinal fluid shunt infection. Neurosurgery 1980; 7:459.</a></li><li><a class="nounderline abstract_t">James HE, Walsh JW, Wilson HD, Connor JD. The management of cerebrospinal fluid shunt infections: a clinical experience. Acta Neurochir (Wien) 1981; 59:157.</a></li><li><a class="nounderline abstract_t">Schreffler RT, Schreffler AJ, Wittler RR. Treatment of cerebrospinal fluid shunt infections: a decision analysis. Pediatr Infect Dis J 2002; 21:632.</a></li><li><a class="nounderline abstract_t">Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18.</a></li><li><a class="nounderline abstract_t">Pelegrín I, Lora-Tamayo J, Gómez-Junyent J, et al. Management of Ventriculoperitoneal Shunt Infections in Adults: Analysis of Risk Factors Associated With Treatment Failure. Clin Infect Dis 2017; 64:989.</a></li><li><a class="nounderline abstract_t">Gombert ME, Landesman SH, Corrado ML, et al. Vancomycin and rifampin therapy for Staphylococcus epidermidis meningitis associated with CSF shunts: report of three cases. J Neurosurg 1981; 55:633.</a></li><li><a class="nounderline abstract_t">Jorgenson L, Reiter PD, Freeman JE, et al. Vancomycin disposition and penetration into ventricular fluid of the central nervous system following intravenous therapy in patients with cerebrospinal devices. Pediatr Neurosurg 2007; 43:449.</a></li><li><a class="nounderline abstract_t">Wang Q, Shi Z, Wang J, et al. Postoperatively administered vancomycin reaches therapeutic concentration in the cerebral spinal fluid of neurosurgical patients. Surg Neurol 2008; 69:126.</a></li><li><a class="nounderline abstract_t">Pfausler B, Spiss H, Beer R, et al. Treatment of staphylococcal ventriculitis associated with external cerebrospinal fluid drains: a prospective randomized trial of intravenous compared with intraventricular vancomycin therapy. J Neurosurg 2003; 98:1040.</a></li><li><a class="nounderline abstract_t">Aguilar J, Urday-Cornejo V, Donabedian S, et al. Staphylococcus aureus meningitis: case series and literature review. Medicine (Baltimore) 2010; 89:117.</a></li><li><a class="nounderline abstract_t">Ntziora F, Falagas ME. Linezolid for the treatment of patients with central nervous system infection. Ann Pharmacother 2007; 41:296.</a></li><li><a class="nounderline abstract_t">Myrianthefs P, Markantonis SL, Vlachos K, et al. Serum and cerebrospinal fluid concentrations of linezolid in neurosurgical patients. Antimicrob Agents Chemother 2006; 50:3971.</a></li><li><a class="nounderline abstract_t">Beer R, Engelhardt KW, Pfausler B, et al. Pharmacokinetics of intravenous linezolid in cerebrospinal fluid and plasma in neurointensive care patients with staphylococcal ventriculitis associated with external ventricular drains. Antimicrob Agents Chemother 2007; 51:379.</a></li><li><a class="nounderline abstract_t">Nagashima G, Okamoto N, Okuda M, et al. Effect of linezolid against postneurosurgical meningitis caused by methicillin-resistant Staphylococcus epidermidis: case report. J Infect Chemother 2008; 14:147.</a></li><li><a class="nounderline abstract_t">Levitz RE, Quintiliani R. Trimethoprim-sulfamethoxazole for bacterial meningitis. Ann Intern Med 1984; 100:881.</a></li><li><a class="nounderline abstract_t">Dudley MN, Levitz RE, Quintiliani R, et al. Pharmacokinetics of trimethoprim and sulfamethoxazole in serum and cerebrospinal fluid of adult patients with normal meninges. Antimicrob Agents Chemother 1984; 26:811.</a></li><li><a class="nounderline abstract_t">Gerber P, Stucki A, Acosta F, et al. Daptomycin is more efficacious than vancomycin against a methicillin-susceptible Staphylococcus aureus in experimental meningitis. J Antimicrob Chemother 2006; 57:720.</a></li><li><a class="nounderline abstract_t">Cottagnoud P, Pfister M, Acosta F, et al. Daptomycin is highly efficacious against penicillin-resistant and penicillin- and quinolone-resistant pneumococci in experimental meningitis. Antimicrob Agents Chemother 2004; 48:3928.</a></li><li><a class="nounderline abstract_t">Villani P, Regazzi MB, Marubbi F, et al. Cerebrospinal fluid linezolid concentrations in postneurosurgical central nervous system infections. Antimicrob Agents Chemother 2002; 46:936.</a></li><li><a class="nounderline abstract_t">Gallagher RM, Pizer B, Ellison JA, Riordan FA. Glycopeptide insensitive Staphylococcus aureus subdural empyema treated with linezolid and rifampicin. J Infect 2008; 57:410.</a></li><li><a class="nounderline abstract_t">Kessler AT, Kourtis AP. Treatment of meningitis caused by methicillin-resistant Staphylococcus aureus with linezolid. Infection 2007; 35:271.</a></li><li><a class="nounderline abstract_t">Naesens R, Ronsyn M, Druwé P, et al. Central nervous system invasion by community-acquired meticillin-resistant Staphylococcus aureus. J Med Microbiol 2009; 58:1247.</a></li><li><a class="nounderline abstract_t">Vartzelis G, Theodoridou M, Daikos GL, et al. Brain abscesses complicating Staphylococcus aureus sepsis in a premature infant. Infection 2005; 33:36.</a></li><li><a class="nounderline abstract_t">Lee DH, Palermo B, Chowdhury M. Successful treatment of methicillin-resistant staphylococcus aureus meningitis with daptomycin. Clin Infect Dis 2008; 47:588.</a></li><li><a class="nounderline abstract_t">Wallace WR, Sander AW, Licitra C, et al. Methicillin-resistant Staphylococcus aureus meningitis successfully treated with daptomycin. Infect Dis Clin North Am 2009; 17:69.</a></li><li><a class="nounderline abstract_t">Rogers EA, Kimia A, Madsen JR, et al. Predictors of ventricular shunt infection among children presenting to a pediatric emergency department. Pediatr Emerg Care 2012; 28:405.</a></li><li><a class="nounderline abstract_t">Schade RP, Schinkel J, Roelandse FW, et al. Lack of value of routine analysis of cerebrospinal fluid for prediction and diagnosis of external drainage-related bacterial meningitis. J Neurosurg 2006; 104:101.</a></li><li><a class="nounderline abstract_t">Pfisterer W, Mühlbauer M, Czech T, Reinprecht A. Early diagnosis of external ventricular drainage infection: results of a prospective study. J Neurol Neurosurg Psychiatry 2003; 74:929.</a></li><li><a class="nounderline abstract_t">Walti LN, Conen A, Coward J, et al. Characteristics of infections associated with external ventricular drains of cerebrospinal fluid. J Infect 2013; 66:424.</a></li><li><a class="nounderline abstract_t">Choksey MS, Malik IA. Zero tolerance to shunt infections: can it be achieved? J Neurol Neurosurg Psychiatry 2004; 75:87.</a></li><li><a class="nounderline abstract_t">Bratzler DW, Dellinger EP, Olsen KM, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Surg Infect (Larchmt) 2013; 14:73.</a></li><li><a class="nounderline abstract_t">Ratilal B, Costa J, Sampaio C. Antibiotic prophylaxis for surgical introduction of intracranial ventricular shunts. Cochrane Database Syst Rev 2006; :CD005365.</a></li><li><a class="nounderline abstract_t">Prabhu VC, Kaufman HH, Voelker JL, et al. Prophylactic antibiotics with intracranial pressure monitors and external ventricular drains: a review of the evidence. Surg Neurol 1999; 52:226.</a></li><li><a class="nounderline abstract_t">Morris A, Low DE. Nosocomial bacterial meningitis, including central nervous system shunt infections. Infect Dis Clin North Am 1999; 13:735.</a></li><li><a class="nounderline abstract_t">Ragel BT, Browd SR, Schmidt RH. Surgical shunt infection: significant reduction when using intraventricular and systemic antibiotic agents. J Neurosurg 2006; 105:242.</a></li><li><a class="nounderline abstract_t">Klimo P Jr, Van Poppel M, Thompson CJ, et al. Pediatric hydrocephalus: systematic literature review and evidence-based guidelines. Part 6: Preoperative antibiotics for shunt surgery in children with hydrocephalus: a systematic review and meta-analysis. J Neurosurg Pediatr 2014; 14 Suppl 1:44.</a></li><li><a class="nounderline abstract_t">Stenager E, Gerner-Smidt P, Kock-Jensen C. Ventriculostomy-related infections--an epidemiological study. Acta Neurochir (Wien) 1986; 83:20.</a></li><li><a class="nounderline abstract_t">Lakomkin N, Hadjipanayis CG. The Role of Prophylactic Intraventricular Antibiotics in Reducing the Incidence of Infection and Revision Surgery in Pediatric Patients Undergoing Shunt Placement. Neurosurgery 2021; 88:301.</a></li><li><a class="nounderline abstract_t">Raygor KP, Oh T, Hwang JY, et al. Ventriculoperitoneal shunt infection rates using a standard surgical technique, including topical and intraventricular vancomycin: the Children's Hospital Oakland experience. J Neurosurg Pediatr 2020; 26:504.</a></li><li><a class="nounderline abstract_t">Klimo P Jr, Thompson CJ, Ragel BT, Boop FA. Antibiotic-impregnated shunt systems versus standard shunt systems: a meta- and cost-savings analysis. J Neurosurg Pediatr 2011; 8:600.</a></li><li><a class="nounderline abstract_t">Klimo P Jr, Thompson CJ, Baird LC, et al. Pediatric hydrocephalus: systematic literature review and evidence-based guidelines. Part 7: Antibiotic-impregnated shunt systems versus conventional shunts in children: a systematic review and meta-analysis. J Neurosurg Pediatr 2014; 14 Suppl 1:53.</a></li><li><a class="nounderline abstract_t">Thomas R, Lee S, Patole S, Rao S. Antibiotic-impregnated catheters for the prevention of CSF shunt infections: a systematic review and meta-analysis. Br J Neurosurg 2012; 26:175.</a></li><li><a class="nounderline abstract_t">Parker SL, Anderson WN, Lilienfeld S, et al. Cerebrospinal shunt infection in patients receiving antibiotic-impregnated versus standard shunts. J Neurosurg Pediatr 2011; 8:259.</a></li><li><a class="nounderline abstract_t">Sonabend AM, Korenfeld Y, Crisman C, et al. Prevention of ventriculostomy-related infections with prophylactic antibiotics and antibiotic-coated external ventricular drains: a systematic review. Neurosurgery 2011; 68:996.</a></li><li><a class="nounderline abstract_t">Mallucci CL, Jenkinson MD, Conroy EJ, et al. Antibiotic or silver versus standard ventriculoperitoneal shunts (BASICS): a multicentre, single-blinded, randomised trial and economic evaluation. Lancet 2019; 394:1530.</a></li><li><a class="nounderline abstract_t">Wong GK, Poon WS, Wai S, et al. Failure of regular external ventricular drain exchange to reduce cerebrospinal fluid infection: result of a randomised controlled trial. J Neurol Neurosurg Psychiatry 2002; 73:759.</a></li><li><a class="nounderline abstract_t">Holloway KL, Barnes T, Choi S, et al. Ventriculostomy infections: the effect of monitoring duration and catheter exchange in 584 patients. J Neurosurg 1996; 85:419.</a></li><li><a class="nounderline abstract_t">Kestle JR, Riva-Cambrin J, Wellons JC 3rd, et al. A standardized protocol to reduce cerebrospinal fluid shunt infection: the Hydrocephalus Clinical Research Network Quality Improvement Initiative. J Neurosurg Pediatr 2011; 8:22.</a></li><li><a class="nounderline abstract_t">Kestle JR, Holubkov R, Douglas Cochrane D, et al. A new Hydrocephalus Clinical Research Network protocol to reduce cerebrospinal fluid shunt infection. J Neurosurg Pediatr 2016; 17:391.</a></li><li><a class="nounderline abstract_t">Flint AC, Toossi S, Chan SL, et al. A Simple Infection Control Protocol Durably Reduces External Ventricular Drain Infections to Near-Zero Levels. World Neurosurg 2017; 99:518.</a></li><li><a class="nounderline abstract_t">Flint AC, Rao VA, Renda NC, et al. A simple protocol to prevent external ventricular drain infections. Neurosurgery 2013; 72:993.</a></li></ol></div><div id="topicVersionRevision">Topic 1286 Version 36.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6694707" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Ventriculostomy-related infections. A prospective epidemiologic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12652386" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Risk factors for pediatric ventriculoperitoneal shunt infection and predictors of infectious pathogens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18484878" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Characteristics and treatment outcome of cerebrospinal fluid shunt-associated infections in adults: a retrospective analysis over an 11-year period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28203777" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : 2017 Infectious Diseases Society of America's Clinical Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6502235" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Factors causing acute shunt infection. Computer analysis of 1174 operations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3644805" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Operative related infection rates for ventriculoperitoneal shunt procedures in a children's hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2702346" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Cerebrospinal fluid shunt infections. Report of 41 cases and a critical review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8491526" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : CSF shunt infections in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8398847" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : A search for determinants of cerebrospinal fluid shunt survival: retrospective analysis of a 14-year institutional experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12053043" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Cerebrospinal fluid shunt survival and etiology of failures: a seven-year institutional experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16534646" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Cerebrospinal fluid shunt infection: risk factors and long-term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20071704" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Nosocomial bacterial meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24661340" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Risk factors for first cerebrospinal fluid shunt infection: findings from a multi-center prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30497165" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Gastrostomy tube placement increases the risk of ventriculoperitoneal shunt infection: a multiinstitutional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10461072" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Does age or other factors influence the incidence of ventriculoperitoneal shunt infections?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/501424" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Long-term analysis of cerebrospinal fluid shunt infections. A 25-year experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1127260" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Infections of cerebrospinal fluid shunts: epidemiology, clinical manifestations, and therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6739339" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Cerebrospinal fluid shunt infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3624904" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Coagulase-negative staphylococci isolated from cerebrospinal fluid shunts: importance of slime production, species identification, and shunt removal to clinical outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3624905" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Clinical significance of a test for slime production in ventriculoperitoneal shunt infections caused by coagulase-negative staphylococci.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11712094" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Ventriculitis complicating use of intraventricular catheters in adult neurosurgical patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10426184" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Nosocomial meningitis in children after ventriculoperitoneal shunt insertion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10452648" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Successful treatment of ceftazidime-resistant Klebsiella pneumoniae ventriculitis with intravenous meropenem and intraventricular polymyxin B: case report and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9636880" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Intraventricular quinupristin/dalfopristin for the treatment of vancomycin-resistant Enterococcus faecium shunt infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12368984" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Late shunt infection: incidence, pathogenesis, and therapeutic implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10681682" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Late shunt infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8448291" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Ventricular CSF shunt infections associated with Corynebacterium jeikeium: report of three cases and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8011309" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Treatment of shunt-related cerebral ventriculitis due to Corynebacterium jeikeium with vancomycin administered intraventricularly. Case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9202275" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Stenotrophomonas maltophilia meningitis. Report of two cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15667915" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Ventriculoperitoneal shunt infection due to Serratia marcescens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9577978" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Meningitis due to Ochrobactrum anthropi: an emerging nosocomial pathogen. A report of 3 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9453032" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Ventricular shunt infection and meningitis due to Bacillus cereus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10414479" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Mycobacterium fortuitum infection of ventriculoperitoneal shunt.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7888533" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Fungal infection of ventriculoperitoneal shunts in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15991051" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Role of biofilms in neurosurgical device-related infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22753376" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Biofilm-infected intracerebroventricular shunts elicit inflammation within the central nervous system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6886752" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Cerebrospinal fluid shunt infections. A review of 35 infections in 32 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6831779" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Shunt nephritis: report of two cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6737057" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Shunt fluid examination: risks and benefits in the evaluation of shunt malfunction and infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9399503" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Clinical utility of broth cultures of cerebrospinal fluid from patients at risk for shunt infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11419501" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Predictors of ventriculoperitoneal shunt pathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12741733" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Early diagnosis of ventriculoperitoneal shunt infections and malfunctions in children with hydrocephalus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1885971" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Ventricular cerebrospinal fluid eosinophilia in children with ventriculoperitoneal shunts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18377304" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Cerebrospinal fluid eosinophilia in children with ventricular shunts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21160233" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Eosinophil activation in the cerebrospinal fluid of children with shunt obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30899767" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Impact of Antibiotic Therapy in the Microbiological Yield of Healthcare-Associated Ventriculitis and Meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25445228" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : The diagnostic value of cerebrospinal fluids procalcitonin and lactate for the differential diagnosis of post-neurosurgical bacterial meningitis and aseptic meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28458153" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : CSF lactate alone is not a reliable indicator of bacterial ventriculitis in patients with ventriculostomies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28789958" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Diagnosis of ventriculostomy-related infection: Is cerebrospinal fluid lactate measurement a useful tool?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11694798" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : The treatment of cerebrospinal fluid shunt infections. Results from a practice survey of the American Society of Pediatric Neurosurgeons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7003434" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Prospective randomized study of therapy in cerebrospinal fluid shunt infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7340429" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : The management of cerebrospinal fluid shunt infections: a clinical experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12237594" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Treatment of cerebrospinal fluid shunt infections: a decision analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21208910" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28329191" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Management of Ventriculoperitoneal Shunt Infections in Adults: Analysis of Risk Factors Associated With Treatment Failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7277012" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Vancomycin and rifampin therapy for Staphylococcus epidermidis meningitis associated with CSF shunts: report of three cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17992031" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Vancomycin disposition and penetration into ventricular fluid of the central nervous system following intravenous therapy in patients with cerebrospinal devices.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17976701" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Postoperatively administered vancomycin reaches therapeutic concentration in the cerebral spinal fluid of neurosurgical patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12744364" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Treatment of staphylococcal ventriculitis associated with external cerebrospinal fluid drains: a prospective randomized trial of intravenous compared with intraventricular vancomycin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20517182" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Staphylococcus aureus meningitis: case series and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17284501" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Linezolid for the treatment of patients with central nervous system infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16982782" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Serum and cerebrospinal fluid concentrations of linezolid in neurosurgical patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17043116" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Pharmacokinetics of intravenous linezolid in cerebrospinal fluid and plasma in neurointensive care patients with staphylococcal ventriculitis associated with external ventricular drains.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18622679" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Effect of linezolid against postneurosurgical meningitis caused by methicillin-resistant Staphylococcus epidermidis: case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6372565" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Trimethoprim-sulfamethoxazole for bacterial meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6335381" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Pharmacokinetics of trimethoprim and sulfamethoxazole in serum and cerebrospinal fluid of adult patients with normal meninges.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16459345" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Daptomycin is more efficacious than vancomycin against a methicillin-susceptible Staphylococcus aureus in experimental meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15388454" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Daptomycin is highly efficacious against penicillin-resistant and penicillin- and quinolone-resistant pneumococci in experimental meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11850294" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Cerebrospinal fluid linezolid concentrations in postneurosurgical central nervous system infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18703232" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Glycopeptide insensitive Staphylococcus aureus subdural empyema treated with linezolid and rifampicin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17646913" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Treatment of meningitis caused by methicillin-resistant Staphylococcus aureus with linezolid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19528145" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Central nervous system invasion by community-acquired meticillin-resistant Staphylococcus aureus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15750759" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Brain abscesses complicating Staphylococcus aureus sepsis in a premature infant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18636964" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Successful treatment of methicillin-resistant staphylococcus aureus meningitis with daptomycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Methicillin-resistant Staphylococcus aureus meningitis successfully treated with daptomycin</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22531186" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Predictors of ventricular shunt infection among children presenting to a pediatric emergency department.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16509153" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Lack of value of routine analysis of cerebrospinal fluid for prediction and diagnosis of external drainage-related bacterial meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12810782" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Early diagnosis of external ventricular drainage infection: results of a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23313468" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Characteristics of infections associated with external ventricular drains of cerebrospinal fluid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14707314" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Zero tolerance to shunt infections: can it be achieved?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23461695" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Clinical practice guidelines for antimicrobial prophylaxis in surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16856095" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Antibiotic prophylaxis for surgical introduction of intracranial ventricular shunts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10511079" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Prophylactic antibiotics with intracranial pressure monitors and external ventricular drains: a review of the evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10470564" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Nosocomial bacterial meningitis, including central nervous system shunt infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17219829" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Surgical shunt infection: significant reduction when using intraventricular and systemic antibiotic agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25988782" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Pediatric hydrocephalus: systematic literature review and evidence-based guidelines. Part 6: Preoperative antibiotics for shunt surgery in children with hydrocephalus: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3799246" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Ventriculostomy-related infections--an epidemiological study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32985657" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : The Role of Prophylactic Intraventricular Antibiotics in Reducing the Incidence of Infection and Revision Surgery in Pediatric Patients Undergoing Shunt Placement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32707540" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Ventriculoperitoneal shunt infection rates using a standard surgical technique, including topical and intraventricular vancomycin: the Children's Hospital Oakland experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22132919" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Antibiotic-impregnated shunt systems versus standard shunt systems: a meta- and cost-savings analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25988783" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Pediatric hydrocephalus: systematic literature review and evidence-based guidelines. Part 7: Antibiotic-impregnated shunt systems versus conventional shunts in children: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21973061" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Antibiotic-impregnated catheters for the prevention of CSF shunt infections: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21882917" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Cerebrospinal shunt infection in patients receiving antibiotic-impregnated versus standard shunts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21221026" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Prevention of ventriculostomy-related infections with prophylactic antibiotics and antibiotic-coated external ventricular drains: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31522843" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Antibiotic or silver versus standard ventriculoperitoneal shunts (BASICS): a multicentre, single-blinded, randomised trial and economic evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12438486" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Failure of regular external ventricular drain exchange to reduce cerebrospinal fluid infection: result of a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8751626" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Ventriculostomy infections: the effect of monitoring duration and catheter exchange in 584 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21721884" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : A standardized protocol to reduce cerebrospinal fluid shunt infection: the Hydrocephalus Clinical Research Network Quality Improvement Initiative.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26684763" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : A new Hydrocephalus Clinical Research Network protocol to reduce cerebrospinal fluid shunt infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28012890" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : A Simple Infection Control Protocol Durably Reduces External Ventricular Drain Infections to Near-Zero Levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23467249" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : A simple protocol to prevent external ventricular drain infections.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
